title: Partial splenic embolization for the treatment of chronic idiopathic thrombocytopenic purpura.
abstract: OBJECTIVE
  The purpose of this study was to assess the effectiveness of partial splenic embolization in the treatment of chronic idiopathic thrombocytopenic purpura.
  
  
  METHODS
  Twenty-six patients with chronic idiopathic thrombocytopenic purpura underwent partial splenic embolization and were followed up for 6-61 months. The condition was refractory to steroids in 20 of 26 patients. The other six patients, in whom a response to steroids was shown, could not be withdrawn from steroid therapy because their platelet counts decreased with any decrease in steroid dose. Five of 26 patients underwent splenectomy after partial splenic embolization, and the other patients were followed up without medical treatment until platelet counts decreased below 3 x 10(10)/l. The therapeutic effect of partial splenic embolization was defined on the basis of the platelet count at the last follow-up after partial splenic embolization: complete response, greater than 10 x 10(10)/l; partial response, 5 x 10(10)/l to 10 x 10(10)/l; and no response, less than 5 x 10(10)/l without medication.
  
  
  RESULTS
  Partial splenic embolization brought a complete response in seven (33%) of 21 patients, a partial response in eight (38%), and no response in six (29%). In four of five patients, who later underwent splenectomy, response to partial splenic embolization was coincident with the response to splenectomy. No serious complications occurred, but minor complications such as abdominal pain, fever, and nausea were observed in most patients.
  
  
  CONCLUSIONS
  This study suggests that partial splenic embolization might be useful as an alternative to splenectomy in the treatment of chronic idiopathic thrombocytopenic purpura.
authors.affiliation: First Department of Surgery, School of Medicine, Chiba University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Miyazaki
authors.forename: H
authors.initials: H
authors.lastname: Itoh
authors.forename: T
authors.initials: T
authors.lastname: Kaiho
authors.forename: S
authors.initials: S
authors.lastname: Ohtawa
authors.forename: S
authors.initials: S
authors.lastname: Ambiru
authors.forename: S
authors.initials: S
authors.lastname: Hayashi
authors.forename: N
authors.initials: N
authors.lastname: Nakajima
authors.forename: H
authors.initials: H
authors.lastname: Oh
authors.forename: T
authors.initials: T
authors.lastname: Asai
authors.forename: T
authors.initials: T
authors.lastname: Iseki
mesh_terms: D000328:Adult; D000667:Ampicillin / Q000008:administration & dosage; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D005781:Gelatin Sponge, Absorbable; D006801:Humans; D008297:Male; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy*; D015641:Radiography, Interventional; D013157:Splenic Artery / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed
chemical_list: D000667:Ampicillin